ANDA 204055, held by Epic Pharma. Epinastine Hydrochloride.
As of Nov 21, 2026, ANDA 204055 (Epinastine Hydrochloride), held by Epic Pharma, was first approved by FDA on May 5, 2017, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 5, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Epinastine Hydrochloride0.05% · solution/drops;ophthalmic | Epinastine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters